- Home
- PRPO vs ENSC Comparison
PRPO vs ENSC Comparison
Compare PRPO & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- ENSC
- Stock Information
- Founded
- PRPO N/A
- ENSC 2003
- Country
- PRPO United States
- ENSC United States
- Employees
- PRPO N/A
- ENSC N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- ENSC Health Care
- Exchange
- PRPO Nasdaq
- ENSC Nasdaq
- Market Cap
- PRPO 8.8M
- ENSC 9.8M
- IPO Year
- PRPO N/A
- ENSC N/A
- Fundamental
- Price
- PRPO $6.51
- ENSC $7.77
- Analyst Decision
- PRPO
- ENSC
- Analyst Count
- PRPO 0
- ENSC 0
- Target Price
- PRPO N/A
- ENSC N/A
- AVG Volume (30 Days)
- PRPO 8.3K
- ENSC 100.5K
- Earning Date
- PRPO 11-06-2024
- ENSC 03-14-2025
- Dividend Yield
- PRPO N/A
- ENSC N/A
- EPS Growth
- PRPO N/A
- ENSC N/A
- EPS
- PRPO N/A
- ENSC N/A
- Revenue
- PRPO $17,411,000.00
- ENSC $4,421,404.00
- Revenue This Year
- PRPO $75.18
- ENSC $89.78
- Revenue Next Year
- PRPO N/A
- ENSC N/A
- P/E Ratio
- PRPO N/A
- ENSC N/A
- Revenue Growth
- PRPO 31.31
- ENSC 40.41
- 52 Week Low
- PRPO $4.31
- ENSC $2.12
- 52 Week High
- PRPO $7.30
- ENSC $30.90
- Technical
- Relative Strength Index (RSI)
- PRPO 64.52
- ENSC 50.09
- Support Level
- PRPO $6.00
- ENSC $6.75
- Resistance Level
- PRPO $6.34
- ENSC $9.57
- Average True Range (ATR)
- PRPO 0.37
- ENSC 0.73
- MACD
- PRPO 0.09
- ENSC -0.13
- Stochastic Oscillator
- PRPO 100.00
- ENSC 36.17
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.